6-Gingerol alleviates exaggerated vasoconstriction in diabetic rat aorta through direct vasodilation and nitric oxide generation

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 6019-6026

  Ghareib, Salah A ^a   El Bassossy, Hany M ^a,b   Elberry, Ahmed A ^a,c   Azhar, Ahmad ^a   Watson, Malcolm L ^d   Banjar, Zainy Mohammed ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Zagazig University   (Egypt)

^c BENI SUEF UNIVERSITY   (Egypt)

^d University of Bath   (United Kingdom)

Author keywords

6 gingerol; Advanced glycation end products; Diabetes; Nitric oxide; Vascular complications; Vasorelaxant

Indexed keywords

(6) GINGEROL; ADVANCED GLYCATION END PRODUCT; METHYLGLYOXAL; N(G) NITROARGININE METHYL ESTER; TETRYLAMMONIUM CHLORIDE; CATECHOL DERIVATIVE; FATTY ALCOHOL; GINGEROL; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HEART MUSCLE RELAXATION; MALE; NONHUMAN; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASOCONSTRICTION; VASODILATATION; ANIMAL; AORTA; BIOSYNTHESIS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ANIMALS; AORTA; CATECHOLS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTION; VASODILATION;

EID: 84947092991     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S94346     Document Type: Article

References (33)

1. International Diabetes Federation 2014 http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures. Accessed, 10 August 2015.
2. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014;130:1110-1130.
3. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study Experience. Diabetes. 2006;55:1463-1469.
4. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence and risk factors. Diabetes Care. 2001;24:1614-1619.
5. Janghorbani M, Rexrode KM, Logroscino G. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care. 2007;30:1730-1735.
6. Bjornstad P, Cherney D, Maahs DM. Early diabetic nephropathy in type 1 diabetes - new insights. Curr Opin Endocrinol Diabetes Obes. 2014;21:279-286.
7. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26:226-229.
8. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
9. Nugent AG, McGurk C, Hayes JR, Johnston GD. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes. 1996;45:105-107.
10. Badreldin HA, Gerald B, Musbah OT, Abderrahim N. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46:409-420.
11. Duke JA. Handbook of Medicinal Herbs. Boca Raton, FL: CRC Press; 2002:327-329.
12. Langner E, Greifenberg S, Gruenwald J. Ginger: history and use. Adv Ther. 1998;15:25-44.
13. Dugasani S, Pichika MR, Nadarajah VD, Balijepalli MK, Tandra S, Korlakunta JN. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010;127:515-520.
14. Chakraborty D, Mukherjee A, Sikdar S, Paul A, Ghosh S, Khuda-Bukhsh AR. [6]-Gingerol isolated from ginger attenuates sodium arsenite induced oxidative stress and plays a corrective role in improving insulin signaling in mice. Toxicol Lett. 2012;210:34-43.
15. Kim EC, Min JK, Kim TY, et al. [6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 2005;335:300-308.
16. Lee HS, Seo EY, Kang NE, Kim WK. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J Nutr Biochem. 2008;19:313-319.
17. Liao YR, Leu YL, Chan YY, Kuo PC, Wu TS. Anti-platelet aggregation and vasorelaxing effects of the constituents of the rhizomes of Zingiber officinale. Molecules. 2012;17(8):8928-8937.
18. El-Bassossy HM, El-Fawal R, Fahmy A. Arginase inhibition alleviates hypertension associated with diabetes: effect on endothelial dependent relaxation and NO production. Vascul Pharmacol. 2012;57:194-200.
19. El-Bassossy HM, El-Moselhy MA, Mahmoud MF. Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:277-285.
20. Mahmoud MF, Hassan NA, El Bassossy HM, Fahmy A. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PLoS One. 2013;8:e63784.
21. Adisakwattana S, Jiphimai P, Prutanopajai P, Chanathong B, Sapwarobol S, Ariyapitipan T. Evaluation of α-glucosidase, α-amylase and protein glycation inhibitory activities of edible plants. Int J Food Sci Nutr. 2010;61:295-305.
22. Abebe W, Harris KH, Macleod KM. Enhanced contractile responses of arteries from diabetic rats to α1-adrenoceptor stimulation in the absence and presence of extracellular calcium. J Cardiovasc Pharmacol. 1990;16:239-248.
23. Ozcelikay AT, Pekiner C, Ari N, Ozturk Y, Ozuari A, Altan VM. The effect of vanadyl treatment on vascular responsiveness of streptozotocin-diabetic rats. Diabetologia. 1994;37:572-578.
24. Zhu BH, Guan YY, Min J, He H. Contractile responses of diabetic rat aorta to phenylephrine at different stages of diabetic duration. Acta Pharmacol Sin. 2001;22:445-449.
25. Buñag RD, Tomita T, Krizsan D. Renovascular beta adrenergic hypersensitivity and hyperinsulinemia in rats with dietary-induced obesity. J Pharmacol Exp Ther. 1990;255(1):325-332.
26. Leung JYT, Kwok EWY, Liu GY, Pang CCY. Attenuated α-adrenoceptor-mediated arterial and venous constrictions in rat models of diabetes. Eur J Pharmacol. 2010;642(1-3):128-133.
27. Orie NN, Aloamaka CP, Iyawe VI. Duration-dependent attenuation of acetylcholine-but not histamine-induced relaxation of the aorta in diabetes mellitus. Gen Pharmacol. 1993;24:329-332.
28. Leo CH, Hart JL, Woodman OL. Impairment of both nitric oxide-mediated and EDHF type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes. Br J Pharmacol. 2011;162:365-377.
29. Mukohda M, Okada M, Hara Y, Yamawaki H. Exploring mechanisms of diabetes-related macrovascular complications: role of methylglyoxal, a metabolite of glucose on regulation of vascular contractility. J Pharmacol Sci. 2012;118:303-310.
30. Xu B, Ji Y, Yao K, Cao YX, Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond). 2005;109(5):439-446.
31. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992;89:12043-12047.
32. Ghayur MN, Gilani AH, Afridi MB, Houghton PJ. Cardiovascular effects of ginger aqueous extract and its phenolic constituents are mediated through multiple pathways. Vascul Pharmacol. 2005;43(4):234-241.
33. El-Bakly WM, Louka ML, El-Halawany AM, Schaalan MF. 6-Gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation. Cancer Chemother Pharmacol. 2012;70(6):833-841.